about
Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosisPropofol versus midazolam for upper gastrointestinal endoscopy in cirrhotic patients: a meta-analysis of randomized controlled trialsPrevention and intervention strategies to alleviate preoperative anxiety in children: a critical review.Relationship between plasma concentration and effect of midazolam after oral and intravenous administration.Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.Automated Detection of Benzodiazepine Dosage in ICU Patients through a Computational Analysis of Electrocardiographic Data.Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers.Pharmacokinetics and bioavailability of midazolam in manIncreased volume of distribution prolongs midazolam half-life.The pharmacokinetics of midazolam in patients with congestive heart failure.Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia.Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers.Midazolam pharmacokinetics following intravenous and buccal administrationPharmacokinetics and metabolism of oral midazolam in preterm infants.Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers.Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.Midazolam does not inhibit association formation, just its storage and strengtheningMidazolam sedation for outpatient fibreoptic endoscopy: evaluation of alfentanil supplementation.Issues in the management of acute agitation: how much current guidelines consider safety?Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans.Pregnancy does not increase CYP3A or P-glycoprotein activity in the non-human primate, Macaca nemestrina.Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Alternative delivery systems for agents to treat acute agitation: progress to date.The emergence of new psychoactive substance (NPS) benzodiazepines: A review.Chemical structure and properties of midazolam compared with other benzodiazepines.Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics.Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.Recovery following sedation with midazolam or diazepam alone or in combination with fentanyl for outpatient surgery.Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis.Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration.Midazolam: kinetics and effects on memory, sensorium, and haemodynamics.Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites.Automated high-capacity on-line extraction and bioanalysis of dried blood spot samples using liquid chromatography/high-resolution accurate mass spectrometry.Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human.The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration.Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes.Midazolam depresses carotid body chemoreceptor activity.
P2860
Q28367522-0858C849-0108-4A56-9C23-9544E480660EQ28543189-0138B04E-93BC-40B8-9C58-63BB06DE4E00Q30358880-928DA9C6-4C2D-44A1-9F13-E20E73614A8BQ30498564-78DD4126-DEF3-49E6-8E47-F524D061A9F9Q31012256-735F281D-27AE-4544-A1F9-31C1ED420A7BQ31054926-3870312F-48E3-41DD-9283-D4B89905C8CFQ31055286-37EAF824-D20E-4B83-AC70-F9165999F03BQ33668215-9DB21DD9-A75C-4934-A92A-483197DA400EQ34227492-75C9DC06-FB54-47E0-A91E-FFBB6116DDCDQ34247690-D76A7172-8ED2-4968-BDBE-3D3E6430C1FBQ34398254-5A5F05EF-BB58-426F-B6E4-D2233BF0CD3EQ34398445-C54E9D01-126F-4100-934C-6B43DB35CE24Q34686236-A672D53A-B1B2-4D72-A4AD-7E03E4714544Q34797473-F86EB494-3A87-4C8A-B2AD-E3A34CEEEE4BQ35802566-1D1E1F73-9D01-4380-B2E0-15E417D2F298Q35803591-9AD4B58F-BFEC-48AD-B606-2F2C54ED7303Q35804041-8AC281D4-97A5-483E-A1FD-FA275CB47B45Q35827012-2C7E4C88-FEA2-4DF0-9A00-322CE01DF8DAQ36663426-C4BE15DB-787A-4F73-BCDA-94B635A4732FQ36815843-36153FB1-7AE9-43C0-BED7-D707DCF3D406Q36821982-A67266C3-DBD4-44F8-A5D6-7244B24D3B74Q37116195-B7135528-2DB4-4C94-AA48-85670DEC1B46Q37268002-FB92E57F-8E59-49B8-B316-3C92017D8543Q37872786-B7A6CAE9-3AAD-47C8-A766-51DBD6A3E420Q38086777-28DF4B35-4048-425A-B274-988EC34A3143Q38154852-7AB14ABF-8D7C-444A-AACB-96A9843A3CA4Q39282924-650C5099-8A18-4411-B0FD-0BF196A88A8CQ40091626-FB2AC105-D604-49FF-9541-ECE673A88C10Q40206942-EBB252F9-A2D2-4F2F-8684-E6C738CC5A79Q40772216-BB47CA19-6D52-4A09-8EA5-0C30458B3E0BQ41774121-F839AD93-43E7-4AE2-8E93-AD8929DF44BAQ41858171-76EB679C-4DC9-4F87-8FD2-8C90AF7883C3Q41966138-633B99F1-738B-4E06-93B3-2A1D0FF489A5Q42659971-85625134-37B8-45FE-B936-BE0BD0EA68DEQ43255755-611BEA68-DA72-48EB-9F62-2947E0A1E2E2Q43508896-90D84CCC-4857-4855-BB6C-A02B3B2968BDQ43699656-C0CFFD53-824A-40F4-A1ED-19F4F604D3ADQ43836988-C790DD4A-DFD8-448A-B5DC-2E55B523DA93Q46402118-75190A98-56A3-4DD0-A1FB-E0F2CFCC5ACCQ46906828-218CC0AF-0355-477D-81F5-B8BEE379CA0C
P2860
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年学术文章
@wuu
1981年学术文章
@zh
1981年学术文章
@zh-cn
1981年学术文章
@zh-hans
1981年学术文章
@zh-my
1981年学术文章
@zh-sg
1981年學術文章
@yue
1981年學術文章
@zh-hant
name
The pharmacokinetics of midazolam in man.
@en
The pharmacokinetics of midazolam in man.
@nl
type
label
The pharmacokinetics of midazolam in man.
@en
The pharmacokinetics of midazolam in man.
@nl
prefLabel
The pharmacokinetics of midazolam in man.
@en
The pharmacokinetics of midazolam in man.
@nl
P356
P1476
The pharmacokinetics of midazolam in man.
@en
P2093
P2888
P304
P356
10.1007/BF00562804
P50
P577
1981-03-01T00:00:00Z